9 December 2020 in IEEE/ASME Transactions on Mechatronics
Objective: To address the challenges of physical sample retrieval from all locations along patients’ gastrointestinal (GI) tracts for studying of interactions between GI microbial communities (microbiomes) and host immune systems. Methods: We propose a novel tetherless, blindly controlled, magnetically actuated capsule for noninvasive sampling of GI microbiomes and liquid digesta. The mesoscale capsule, a soft mobile robot platform, is made from two permanent magnets encapsulated in a soft elastomer and actuated remotely by an external magnet. The capsule is controlled blindly using an external magnet to orient and activate the capsule. Following oral administration, capsules transit the GI tract and are activated at specified locations. The capsule is recovered via routine stool passage and collected samples are processed for downstream analyses (e.g. 16S rRNA surveys, metagenomics, metatranscriptomics and/or metabolomics). The localization of the capsule is estimated using the travelling time and the location of collected microbiomes will be confirmed by downstream analyses. A mathematical model of capsule activation is used to predict capsule activation and guide design optimization. Results: We demonstrate the ability of the capsule to collect samples, as well as maintain sample integrity in vitro, ex vivo, and with twelve capsules in in vivo swine models. Eleven capsules successfully collected digesta (in the range of 18 to 61 mg). Conclusion: The capsule successfully collected and sealed samples. Significance: This sampling apparatus offers a technological advance for the robust sampling of GI tract contents.
7 May 2021 in Frontiers in Physics
Medical ultrasound is one of the most widely used imaging modalities worldwide. Microbubbles, typically ~1–8 μm in diameter, are ultrasound contrast agents confined to the vasculature due to their size. Microbubbles have broadened the scope of medical ultrasound, permitting real-time imaging of the microvasculature for blood flow assessment, molecular imaging, and even non-invasive site-specific therapy. Recently, there has been increasing interest in developing submicron, “nanoscale” agents to extend the utility of medical ultrasound. In this review, we discuss the development of lipid-encapsulated, acoustically responsive, nanobubbles (~200–800 nm in diameter), a next-generation ultrasound contrast agent. First, medical ultrasound and bubble-based contrast agents are introduced, followed by the advantages of scaling down bubble size from an acoustic and biological viewpoint. Next, we present how lipid-encapsulated nanobubbles can be developed toward meeting clinically meaningful endpoints, from agent synthesis and characterization to in vivo considerations. Finally, future opportunities of nanobubbles for advanced applications in ultrasound diagnostic and therapeutic medicine are proposed.
1 January 2019 in Nanotheranostics
Nanoscale perfluorocarbon (PFC) droplets have enormous potential as clinical theranostic agents. They are biocompatible and are currently used in vivo as contrast agents for a variety of medical imaging modalities, including ultrasound, computed tomography, photoacoustic and 19F-magnetic resonance imaging. PFC nanodroplets can also carry molecular and nanoparticulate drugs and be activated in situ by ultrasound or light for targeted therapy. Recently, there has been renewed interest in using PFC nanodroplets for hypoxic tumor reoxygenation towards radiosensitization based on the high oxygen solubility of PFCs. Previous studies showed that tumor oxygenation using PFC agents only occurs in combination with enhanced oxygen breathing. However, recent studies suggest that PFC agents that accumulate in solid tumors can contribute to radiosensitization, presumably due to tumor reoxygenation without enhanced oxygen breathing. In this study, we quantify the impact of oxygenation due to PFC nanodroplet accumulation in tumors alone in comparison with other reoxygenation methodologies, in particular, carbogen breathing.
22 August 2023 in ACS Applied Nano Materials
Characterizing complex biofluids using surface-enhanced Raman spectroscopy (SERS) coupled with machine learning (ML) has been proposed as a powerful tool for point-of-care detection of clinical disease. ML is well-suited to categorizing otherwise uninterpretable, patient-derived SERS spectra that contain a multitude of low concentration, disease-specific molecular biomarkers among a dense spectral background of biological molecules. However, ML can generate false, non-generalizable models when data sets used for model training are inadequate. It is thus critical to determine how different SERS experimental methodologies and workflow parameters can potentially impact ML disease classification of clinical samples. In this study, a label-free, broadband, Ag nanoparticle-based SERS platform was coupled with ML to assess simulated clinical samples for cardiovascular disease (CVD), containing randomized combinations of five key CVD biomarkers at clinically relevant concentrations in serum. Raman spectra obtained at 532, 633, and 785 nm from up to 300 unique samples were classified into physiological and pathological categories using two standard ML models. Label-free SERS and ML could correctly classify randomized CVD samples with high accuracies of up to 90.0% at 532 nm using as few as 200 training samples. Spectra obtained at 532 nm produced the highest accuracies with no significant increase achieved using multiwavelength SERS. Sample preparation and measurement methodologies (e.g., different SERS substrate lots, sample volumes, sample sizes, and known variations in randomization and experimental handling) were shown to strongly influence the ML classification and could artificially increase classification accuracies by as much as 27%. This detailed investigation into the proper application of ML techniques for CVD classification can lead to improved data set acquisition required for the SERS community, such that ML on labeled and robust SERS data sets can be practically applied for future point-of-care testing in patients.
1 July 2021 in Journal of Vascular and Interventional Radiology
1 November 2017 in Nuclear Medicine and Biology